IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Masatsugu Maeda et al. Art Unit: 1633

Serial No.: 10/006,265 Examiner: Patrick S. Riggins

Filed : December 3, 2001 Confirmation No: 5055

Title : NOVEL HEMOPOIETIN RECEPTOR PROTEIN, NR10

MAIL STOP RCE Commissioner for Patents

P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request consideration of the references listed on the attached PTO-1449 form.

This filing is being made with the filing of a Request for Continued Examination. No fee is required.

Respectfully submitted,

Loss C.

Date: 6-21-2006

Jianming Hao Reg. No. 54,694

Customer No. 26161 Fish & Richardson P.C. Telephone: (617) 542-5070 Facsimile: (617) 542-8906

21357746 doc

Substitute Disclosure Form (PTO-1449)

Substitute Form PTO-1449	U.S. Department of Commerce	Attorney's Docket No.	Application No.	
(Modified)	Patent and Trademark Office	14875-096001	10/006,265	
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Masatsugu Maeda et al.		
		Filing Date December 3, 2001	Group Art Unit 1633	
	U.S. Patent	Documents		

	U.S. Patent Documents						
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						

Examiner	Desig.	Document	Publication	Country or				slation
Initial	ID	Number	Date	Patent Office	Class	Subclass	Yes	No
	AJ							
	AK							
	AL							
	AM							
	AN				T			

Foreign Patent Documents or Published Foreign Patent Applications

	Other Documents (include Author, Title, Date, and Place of Publication)			
Examiner Initial	Desig. ID	Document		
	AO	N. Nishimoto et al. "Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy". Blood 95(1):56-61, January 2000.		
	AP	N. Nishimoto et al. "Toxicity, Pharmacokinetics, and Dose-Finding Study of Repetitive Treatement with the Humanized Anti-Interleukin 6 Receptor Antibody MRA in Rheumatoid Arthritis. Phase I/II Clinical Study". The Journal of Rheumatology 30(7):1426-1435, 2003.		
	AQ	K. Sato et al. "Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth". Cancer Research 53:851-856, February 1993.		
	AR	H. Matsuno et al. "Treatment of rheumatoid synovitis with anti-reshaping human interleukin-6 receptor monoclonal antibody". Arthritis & Rheumatism 41(11):2014-2021, November 1998.		
	AS			

Examiner Signature	Date Considered				
EXAMINER: Initials oftation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with					
next communication to applicant.					